跳至主要内容
临床试验/NCT03620604
NCT03620604Unknown不适用

Mid Term Safety and Efficacy of ALTIS® Single Incision Sling for Female SUI. Less Mesh, Same Results.

Instituto de Investigacion Sanitaria La Fe1 个研究点 分布在 1 个国家目标入组 110 人开始时间: 2014年1月1日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
110
试验地点
1
主要终点
Mid term Efficacy/continence

研究概览

简要总结

Prospective, single-arm, non-sponsored, observational single centre trial in a cohort of patients undergoing stress urinary incontinence surgery with ALTIS® procedure. All patients were diagnosed according to clinical reports, physical exploration and urodynamics. Body mass index(BMI) was categorized according to World Health Organization classification. Valsalva leak point pressure was categorized in three groups <60 cmH2O, 60-90 cmH2O and >90 cmH2O). Participants were evaluated post-operatively at 1, 6, 12 and 24 months with physical examination, ICIQ-SF, visual scale of satisfaction(SVS)(0-10). Adverse events were reported in each visit. Multivariate analysis for risk factors of surgery failure was performed.

详细描述

This is a prospective, single -arm, non-sponsored observational single centre trial in a cohort of patients undergoing stress urinary incontinence surgery with ALTIS® procedure. Two urologists, experts in female incontinence surgery, performed all procedures. Safety and efficacy were evaluated. All participants provided written informed consent prior to enrolment.

The investigators recruited female patients aged 35 years or more with urodynamically proven stress urinary incontinence and who had failed to 6 months of non-surgical therapies including behavioural changes and drug therapy. Exclusion criteria were pelvic infection, pelvic organ prolapse ≥Stage 2, prior stress urinary incontinence surgery, neurogenic bladder incontinence, previous pelvic radiotherapy, high post-voiding volume (100 mL in two times) or being pregnant.

Demographic variables (age, number of vaginal deliveries, prior stress urinary incontinence surgery, menopause status, BMI and presence of urge incontinence) were collected. BMI was categorized according to World Health Organization in normal (18,5-24,9 Kg/m2), overweight (25-29,9 Kg/m2) and obese (≥ 30 Kg/m2) patients. For statistical purpose the investigators divided patients into two groups, non-obese (18,5-29,9) Kg/m2) and obese (≥ 30 Kg/m2) patients.

Preoperative assessment included urogynecological history, cough test (stress test with at least 300 mL of bladder volume measured by ultrasound), Spanish validated version of the International Consultation on Incontinence Questionnaire sort form (ICIQ-SF) and urodynamic test (Urodynamic parameters as Valsalva leak point pressure (VLPP), non-inhibited detrusor contractions and post-voiding volume were reflected. VLPP was categorized into three groups <60 cmH2O, 60-90 cmH2O and >90 cmH2O).

Follow up was carried out with physical examination, ICIQ-SF, visual scale of satisfaction and physical examination including cough test. Subjects were evaluated post-operatively at 1, 6, 12 and 24 months. Adverse events, such as vaginal erosion or pain related to the procedure or the device were evaluated at each visit.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
35 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Urodynamically proven stress urinary incontinence
  • Refractory to 6 months of non-surgical therapies including behavioural changes or drug therapy

排除标准

  • Pelvic infection
  • Pelvic organ prolapse ≥Stage 2
  • Prior stress urinary incontinence surgery
  • Neurogenic bladder incontinence,
  • Previous pelvic radiotherapy,
  • High post-voiding volume (100 mL in two times)
  • Pregnant women.

结局指标

主要结局

Mid term Efficacy/continence

时间窗: Assessed at 24 months of follow up

Mid term Efficacy and continence measured with cough test ( Positive or negative)

次要结局

  • De novo urgency(Assessed at visit 6,12,24 months)
  • Voiding disfunction(Assessed every visit at 1,6,12,24 months)
  • Safety and adverse events(Assessed every visit at 1,6,12,24 months)

研究者

发起方
Instituto de Investigacion Sanitaria La Fe
申办方类型
Other
责任方
Principal Investigator
主要研究者

Eduardo Moran

Urologist

Instituto de Investigacion Sanitaria La Fe

研究点 (1)

Loading locations...

相似试验